A Study of DS8201a, an Anti-HER2-Antibody Drug Conjugate (ADC), versus Treatment of Investigator’s Choice for HER2-low Unresectable and/or Metastatic Breast Cancer.
(DESTINY-Breast 04)
https://clinicaltrials.gov/ct2/show/NCT03326674
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
(ASSURE)
https://clinicaltrials.gov/ct2/show/NCT04008706?term=D8220C00008&draw=2&rank=1
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients (MAVIS)
Enrollment on this trial is on hold. Please contact Ironwood Cancer & Research Centers for status update
A Study of Selective Pan-FGFR inhibitor Debio 1347 in Subjects with Solid Tumors Harboring a Fusion of FGFR1, FGFR2, or FGFR3 (FUZE)
https://clinicaltrials.gov/ct2/show/NCT03834220?term=fuze&draw=2&rank=1
A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Subjects Receiving Highly Emetogenic Chemotherapy
http://clinicaltrials.gov/ct2/show/NCT02106494?term=C2013-01&rank=1
For questions, please contact 480-398-7671
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC).
http://clinicaltrials.gov/ct2/show/NCT01657799?term=m10-897&rank=1
Previously treated Hormone receptor-positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy
Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)
Study Record Detail
For questions, please contact 480-398-7671
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC).
http://clinicaltrials.gov/ct2/show/NCT01657799?term=m10-897&rank=1
For questions, please contact 480-398-7671
HER negative ER/PR positive locally advanced or metastatic. Previous tx w/taxane in neo adj or adjuvant, but not metastatic. Any number of previous hormonal therapies allowed. Arm A= Tesetaxel plus a reduced dose of Capecitabine (825 mg/ m2) orally twice daily. Arm B= Approved dose of Capecitabine alone. (Odonate ODO-TE-B301)
https://clinicaltrials.gov/ct2/show/NCT03326674
–HER positive mBC who have received prior treatment with Herceptin and Perjeta and T-DM1 (substudy). Chemo = choice of Capecitabine, eribulin, gemcitabine or vinorelbine. Infusion sub study= Margetuximab monotherapy vs Margetuximab + Chemo. Decreased infusion time from 120 to 30 minutes. Will require ≥4 prior lines (including trastuzumab, pertuzumab and T-DM1). (SOPHIA CP-MGAH22-04)
–NSCLC Registry of Guardant360® use and outcomes. No more than 8 wks from blood collection. Advanced NSCLC or stage I-IIIA, that is recurrent or metastatic. Collect information on how the results from the Guardant360 test affect clinical decisions. Also understanding the outcomes associated with therapies selected for patients whose tumors have specific genetic mutations. (Geode 01-MX-003)
https://clinicaltrials.gov/ct2/show/NCT03477474
–Advanced triple neg. Breast -Progressed after adjuvant or 1 prior line. -Prior taxane required. -No prior anti PD-L1, anti-LAG-3 etc. -No prior Platinum tx. Arm 1: LAG525(400mg) + Spartalizumab (300mg) Arm 2: LAG525 + Spartalizumab + carboplatin Arm 3: LAG525 +Carboplatin
https://clinicaltrials.gov/ct2/show/NCT03499899?term=lag525&draw=2&rank=2
Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)
https://clinicaltrials.gov/ct2/show/NCT02492711?term=CP-MGAH22-04&rank=1
For questions, please contact 480-398-7671.
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1)
https://clinicaltrials.gov/ct2/show/NCT02732119?term=CLEE011XUS29&rank=1
For questions please contact 480-398-7671
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)
http://clinicaltrials.gov/ct2/show/NCT01808573?term=PUMA-NER-1301&rank=1
For questions, please contact 480-398-7671
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)
https://clinicaltrials.gov/ct2/show/NCT02437318?term=CBYL719C2301&rank=1
For questions, please contact 480-398-7671
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
https://clinicaltrials.gov/ct2/show/NCT02941926?term=CLEE011A2404&rank=1
For questions please contact 480-398-7671
A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single-Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer(mTNBC) – (KEYNOTE-119)
https://clinicaltrials.gov/ct2/show/NCT02555657?term=KEYNOTE-119&rank=1
For questions, please contact 480-398-7671
A Randomized Double-blind, Placebo-controlled Study of Palbociclib in Combination With Fulvestrant for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment
https://clinicaltrials.gov/ct2/show/NCT02422615?term=CLEE011F2301&rank=1
For questions, please contact 480-398-7671
This Trial features Dr. Sujith Kalmadi at Ironwood Cancer & Research Centers in the US for enrolling the first subject on a study. To view this trial please follow the link.
A Phase 2, Randomized, Open-Label, Two-Arm Study To Assess The Efficacy And Safety Of The Epigenetic Modifying Effects Of CC-486 (Oral Azacitidine) In Combination With Fulvestrant In Postmenopausal Women With ER+, HER2- Metastatic Breast Cancer Who Have Progressed On An Aromatase Inhibitor
https://clinicaltrials.gov/ct2/show/NCT02374099?term=CC-486-BRSTM-001&rank=1
For questions, please contact 480-398-7671
A Phase III Randomized, Double-Blind, Placebo-Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor-Based Treatment (BELLE 3)
http://clinicaltrials.gov/ct2/show/NCT01633060?term=CBKM120F2303&rank=1
For questions, please contact 480-398-7671
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting
https://clinicaltrials.gov/ct2/show/NCT02246621?term=I3Y-MC-JPBM&rank=1
For questions, please contact 480-398-7671
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer (INCB 18424-268)
http://clinicaltrials.gov/ct2/show/NCT02120417?term=INCB+18424-268&rank=1
For questions, please contact 480-398-7671
A Study to Evaluate the Risk/Benefit of Nab-Paclitaxel in Combination With Gemcitabine or Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (tenacity)
http://clinicaltrials.gov/ct2/show/NCT01881230?term=abi-007&recr=Open&rank=34
For questions, please contact 480-398-7671
A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT01966471?term=BO28407&rank=1
For questions, please contact 480-398-7671
A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
http://clinicaltrials.gov/ct2/show/NCT01958021?term=CLEE011A2301&rank=1
For questions, please contact 480-398-7671
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
http://clinicaltrials.gov/ct2/show/study/NCT01528345?term=CTKI258&rank=8&show_locs=Y#locn
For questions, please contact 480-398-7671
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
http://clinicaltrials.gov/ct2/show/NCT01491737?term=MO27775&rank=1
For questions, please contact 480-398-7671
A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B3271002)
http://clinicaltrials.gov/ct2/show/NCT01989676?term=B3271002&rank=1
For questions, please contact 480-398-7671
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation (BELLE-4
http://clinicaltrials.gov/ct2/show/NCT01572727?term=belle+4&rank=1
For questions, please contact 480-398-7671
A Study of Palbociclib Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3
http://clinicaltrials.gov/ct2/show/NCT01942135?term=paloma+3&rank=1
For questions, please contact 480-398-7671
A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer
http://clinicaltrials.gov/ct2/show/NCT00968968?term=lapatinib+%26+gsk&rank=22
A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing locally advanced or metastatic breast cancer.
http://clinicaltrials.gov/ct2/show/NCT01007942?term=bolero+3&rank=1
A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MDD-DM1 vs. Capecitabine + Lapatinib in Patients with HER2-positive Locally Advanced or Metastatic Breast Cancer who have received Prior Trastuzumab-Based Therapy
http://clinicaltrials.gov/ct2/show/NCT00829166?term=emilia&rank=1
A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First-Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer.
http://clinicaltrials.gov/ct2/show/NCT00876395?term=bolero+1&rank=1
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
http://clinicaltrials.gov/ct2/show/NCT00703326?term=trio-012&rank=1
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
http://www.clinicaltrials.gov/ct2/show/NCT01125566?term=1200.75&rank=1
-2nd line Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine / Oxaliplatin and Bevacizumab. Patients will be stratified according to the subjects’ RAS mutation status and tumor location. Experimental Arm: ABT-165 + FOLFIRI ABT-165, 2.5 mg/kg, plus FOLFIRI Control Arm: Bevacizumab + FOLFIRI bevacizumab, 5 mg/kg, plus FOLFIRI (Abbvie M14-064)
https://clinicaltrials.gov/ct2/show/NCT03368859
For questions regarding this study, please contact 480-398-7671
Study of Ruxolitinib in Colorectal Cancer Patients
http://clinicaltrials.gov/ct2/show/NCT02119676?term=INCB+18424-267&rank=1
For questions, please contact 480-398-7671
An Open-Label, Multi-Center, Randomized Phase 1B/2 Study of PF-05212384 Plus 5-Fluorouracil-Leucovorin-Irinotecan (FOLFIRI) Versus Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer
http://clinicaltrials.gov/ct2/show/NCT01937715?term=B2151007&rank=1
For questions, please contact 480-398-7671
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
http://clinicaltrials.gov/ct2/show/NCT01925274?term=B2151005&rank=
For questions, please contact 480-398-7671
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
http://clinicaltrials.gov/ct2/show/NCT01934361?term=CBKM120E2102&rank=1
For questions, please contact 480-398-7671
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
https://clinicaltrials.gov/ct2/show/NCT02354586?term=PR-30-5020-C&rank=1
For questions please contact 480-398-7671
A Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
http://clinicaltrials.gov/ct2/show/NCT01732913?term=GS-US-313-0124&rank=1
For questions, please contact 480-398-7671
A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer
https://clinicaltrials.gov/ct2/show/NCT02252042?term=KEYNOTE-040&rank=1
For questions please contact 480-398-7671
A Multi-Center, Randomized, Open-Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer® vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting
http://clinicaltrials.gov/ct2/show/NCT01950247?term=1VIT13032&rank=1
For questions, please contact 480-398-7671
An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
https://clinicaltrials.gov/ct2/show/NCT02656303?term=UTX-TGR-304&rank=1
For questions, please contact 480-398-7671
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia (UNITY-CLL)
https://clinicaltrials.gov/ct2/show/NCT02612311?term=UTX-TGR-304&rank=2
For questions, please contact 480-398-7671
A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
https://clinicaltrials.gov/ct2/show/NCT02301156?term=UTX-IB-301&rank=1
For questions please contact 480-398-7671
Screening Protocol to Determine High-risk Cytogenetic Features in Patients With Previously-treated CLL That May be Eligible for TG Therapeutics Trial UTX-IB-301
No website available at this time
For questions, please contact 480-398-7671
A Study of Obinutuzumab + Bendamustine in Patients With Previously Untreated Chronic Lymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02320487?term=ML29538&rank=1
For questions please contact 480-398-7671
Treatment for Previously Treated Chronic Lymphocytic Leukemia (CLL)
A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
https://clinicaltrials.gov/ct2/show/NCT02301156?term=UTX-IB-301&rank=1
Screening Protocol available to determine a high-risk cytogenetic feature in patients with previously-treated CLL
For questions please contact 480-398-7671
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (ATLANTIS)
https://clinicaltrials.gov/ct2/show/NCT02566993?term=PM1183-C-003-14&rank=1
For questions, please contact 480-398-7671.
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
https://clinicaltrials.gov/ct2/show/NCT02486718?term=GO29527&rank=1
For questions please contact 480-398-7671
A Phase II Study of the Combination ofLY3023414 and Necitumumab after First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
https://clinicaltrials.gov/ct2/show/NCT02443337?term=I6A-MC-CBBE&rank=1
For questions, please contact 480-398-7671
A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150]
https://clinicaltrials.gov/ct2/show/NCT02366143?term=GO29436&rank=1
For questions please contact 480-398-7671
A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131]
https://clinicaltrials.gov/ct2/show/NCT02367794?term=GO29437&rank=1
For questions please contact 480-398-7671
A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC)
https://clinicaltrials.gov/ct2/show/NCT02352948?term=D4191C00004&rank=1
For questions, please contact 480-398-7671
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC)
http://clinicaltrials.gov/ct2/show/NCT02125461?term=D4191C00001&rank=1
For questions, please contact 480-398-7671
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
https://clinicaltrials.gov/ct2/show/NCT02119650?term=INCB+18424-266&rank=1
For questions, please contact 480-398-7671
A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone as Second-Line Therapy in Patients With Stage IIIb/IV Non-Squamous Non-Small-Cell Lung Cancer (SUNRISE)
http://clinicaltrials.gov/ct2/show/NCT01999673?term=PPHM1202&rank=1
For questions, please contact 480-398-7671
An Open-Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT02283320?term=BIND-014-007&rank=1
For questions please contact 480-398-7671
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
http://clinicaltrials.gov/ct2/show/NCT02093962?term=TH-CR-415&rank=1
For questions, please contact 480-398-7671
Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral Nintedanib Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent, Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT02231164?term=1199.128&rank=1
For questions, please contact 480-398-7671
An open-label, multi-center, Expanded Treatment Protocol (ETP) of oral LDK378 in adult patients with non-small cell lung cancer (NSCLC) characterized by ALK positivity
http://clinicaltrials.gov/ct2/show/NCT01947608?term=CLDK378A2402&rank=1
An open-label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway
http://clinicaltrials.gov/ct2/show/NCT01297491?term=bkm120&rank=11
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum-Based Chemotherapy.
http://www.clinicaltrials.gov/ct2/show/NCT01523587?term=1200.125&rank=1
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
http://clinicaltrials.gov/ct2/show/study/NCT01456325?term=metlung&rank=2&show_locs=Y#locn
A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination with a Platinum Containing Doublet in Chemotherapy-Naїve Subjects with Stage IV Adenocarcinoma of the Lung.
http://clinicaltrials.gov/ct2/show/NCT01218516?term=morphotek&rank=11
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients with Stage IIIB or IV Non-Small Cell Lung Cancer.
http://clinicaltrials.gov/ct2/show/NCT01362400?term=infinity+pharmaceuticals&rank=3
A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/Carboplatin With or Without Bavituximab in Patients with Previously Untreated Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer http://clinicaltrials.gov/ct2/show/study/NCT01160601?term=peregrine&rank=5#locn
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer http://clinicaltrials.gov/ct2/show/NCT01138163?term=peregrine&rank=12
A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) http://clinicaltrials.gov/ct2/show/NCT00981058?term=squire&rank=1
A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 Versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer Following Progression After, or Intolerance to, at Least One Prior Chemotherapy.
http://clinicaltrials.gov/ct2/show/NCT01360554?term=a7471009&rank=1
A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment http://clinicaltrials.gov/ct2/results?term=m10-301
Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small-Cell Lung Cancer (NSCLC) http://clinicaltrials.gov/ct2/show/NCT01560104?term=m10-898&rank=1
A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) Which Has Relapsed after Rituximab Therapy.
http://clinicaltrials.gov/ct2/show/NCT01294579?term=arzerra&recr=Open&rank=4
For questions, please contact 480-398-7671
A Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
http://clinicaltrials.gov/ct2/show/NCT01732913?term=GS-US-313-0124&rank=1
For questions, please contact 480-398-7671
A Study Evaluating the Efficacy and Safety of Idelalisib(GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
http://clinicaltrials.gov/ct2/show/NCT01732926?term=GS-US-313-0125&rank=1
For questions, please contact 480-398-7671
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)
http://clinicaltrials.gov/ct2/show/NCT01650701?term=RV-FOL-GELARC-0683C&rank=1
For questions, please contact 480-398-7671
A Phase III, Multicenter, Randomized Trial Comparing the Efficacy of GA101 in Combination with CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL). http://clinicaltrials.gov/ct2/show/NCT01287741?term=bo21005&rank=1
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy.
http://clinicaltrials.gov/ct2/show/NCT00790036?term=pillar+2&rank=1
An Open-Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
http://clinicaltrials.gov/ct2/show/NCT01833039?term=ibrutinib+and+mantle+cell&recr=Open&rank=3
A Phase III Study of Pomalidomide and low dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM)
https://clinicaltrials.gov/ct2/show/NCT02576977?term=MK-3475-183&rank=1
For questions, please contact 480-398-7671
MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
http://clinicaltrials.gov/ct2/show/NCT01850524?term=C16014&rank=1
For questions, please contact 480-398-7671
An Expanded Treatment Protocol of Panobinostat (LBH589) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma Who Have Had at Least One Prior Line of Therapy
http://clinicaltrials.gov/ct2/show/NCT02204553?term=CLBH589DUS94X&rank=1
For questions, please contact 480-398-7671
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT – 1)
http://clinicaltrials.gov/ct2/show/NCT01335399?term=CA204-006&rank=1
For questions, please contact 480-398-7671
Second line metastatic pancreatic cancer
A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)
https://clinicaltrials.gov/ct2/show/NCT02117479?term=INCB+18424-362&rank=1
For questions, please contact 480-398-7671
A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Bavituximab in Patients with Previously Untreated Stage IV Pancreatic Cancer.
http://clinicaltrials.gov/ct2/show/NCT01272791?term=pphm+1002&rank=1
Randomized, open-label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK Inhibitor INC424 tablets verSus best available care (The RESPONSE Trial)
http://clinicaltrials.gov/ct2/show/NCT01243944?term=response+trial&recr=Open&rank=1
A Randomized, Double-Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration-Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT02111577?term=SP005&rank=1
For questions, please contact 480-398-7671
An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy – Early Access Protocol.
http://clinicaltrials.gov/ct2/show/study/NCT01217697?term=abiraterone&recr=
A Randomized, Double-blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT02799602?term=17777&rank=1
For questions please contact 480-398-7671.
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
https://clinicaltrials.gov/ct2/show/NCT02531516?term=56021927PCR3003&rank=1
For questions please contact 480-398-7671.
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis
http://clinicaltrials.gov/ct2/show/NCT02142959?term=408+c+1306&rank=1
For questions, please contact 480-398-7671
A Randomized, Multicenter, Prospective, Double-Blind, Sham-Controlled, Study to Evaluate the Efficacy of MuGard™ Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck.
http://clinicaltrials.gov/ct2/show/NCT01283906?term=mugard&rank=1
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma (IMAGE)
http://clinicaltrials.gov/ct2/show/study/NCT01511913?term=IMAGE+melanoma&rank=1
For questions, please contact 480-398-7671
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma (IMAGE)
http://clinicaltrials.gov/ct2/show/NCT01511913?term=CA184-143&rank=1
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
http://clinicaltrials.gov/ct2/show/NCT01306890?term=proceed&rank=4
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920)
https://clinicaltrials.gov/ct2/show/NCT02982954?term=CA209-920&rank=1
For questions please contact 480-398-7671
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02853305?term=KEYNOTE-361&rank=1
For questions, please contact 480-398-7671.
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03374488?term=keytruda+698&rank=1
For questions please contact 480-398-7671.
